Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 2, 2015, Pages 65.e19-65.e25

  Krabbe, Laura Maria ^a,b   Svatek, Robert S ^c   Shariat, Shahrokh F ^a,d   Messing, Edward ^e   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c University of Texas Health Science Center   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Risk factors; Risk stratification; Screening; Sex

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CAUCASIAN; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; NATIONAL LUNG CANCER SCREENING TRIAL; PRIORITY JOURNAL; PROSTATE LUNG COLORECTAL AND OVARIAN CANCER SCREENING TRIAL; RACE DIFFERENCE; RADIOGRAPHY; SEX DIFFERENCE; SMOKING; SMOKING HABIT; TOBACCO; COHORT ANALYSIS; MASS SCREENING; RISK FACTOR; UNITED STATES; URINARY BLADDER NEOPLASMS;

AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84923558670     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.06.009     Document Type: Article

References (23)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Brown T., Slack R., Rushton L. Occupational cancer in Britain. Urinary tract cancers: bladder and kidney. Br J Cancer 2012, 107(Suppl. 1):S76-S84.
3. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013, 63:234-241.
4. Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. J Am Med Assoc 2011, 306:737-745.
5. Messing E.M., Young T.B., Hunt V.B., Wehbie J.M., Rust P. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 1989, 64:2361-2367.
6. Britton J.P., Dowell A.C., Whelan P., Harris C.M. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992, 148:788-790.
7. Bangma C.H., Loeb S., Busstra M., Zhu X., Bouazzaoui S.E., Refos J., et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol 2013, 64(1):41-47. doi: 10.1016/j.eururo.2013.02.036.
8. Lotan Y., Elias K., Svatek R.S., Bagrodia A., Nuss G., Moran B., et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009, 182:52-57. [discussion 8].
9. Hedelin H., Jonsson K., Salomonsson K., Boman H. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol 2006, 40:26-30.
10. Larre S., Catto J.W., Cookson M.S., Messing E.M., Shariat S.F., Soloway M.S., et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 2013, 63(6):1049-1058. doi: 10.1016/j.eururo.2012.12.062.
11. Prorok P.C., Andriole G.L., Bresalier R.S., Buys S.S., Chia D., Crawford E.D., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000, 21:273S-309S.
12. Aberle D.R., Berg C.D., Black W.C., Church T.R., Fagerstrom R.M., Galen B., et al. The National Lung Screening Trial: overview and study design. Radiology 2011, 258:243-253.
13. Weissfeld J.L., Schoen R.E., Pinsky P.F., Bresalier R.S., Church T., Yurgalevitch S., et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005, 97:989-997.
14. Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, et al, editors. Screening for Colorectal Cancer: An Updated Systematic Review. Rockville, MD: Agency for Healthcare Research and Quality (US); 2008 [Report No. 08-05-05124-EF-1].
15. Lughezzani G., Burger M., Margulis V., Matin S.F., Novara G., Roupret M., et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012, 62:100-114.
16. Vickers A.J., Bennette C., Kibel A.S., Black A., Izmirlian G., Stephenson A.J., et al. Who should be included in a clinical trial of screening for bladder cancer? a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer 2013, 119:143-149.
17. Mir M.C., Stephenson A.J., Grubb R.L., Black A., Kibel A.S., Izmirlian G. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer (PLCO) screening trial participants. Cancer Epidemiol Biomarkers Prev 2013, 22(12):2241-2249. doi: 10.1158/1055-9965.EPI-13-0632.
18. Lotan Y., Svatek R.S., Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population? a cost per life-year saved analysis. Cancer 2006, 107:982-990.
19. Hartge P., Harvey E.B., Linehan W.M., Silverman D.T., Sullivan J.W., Hoover R.N., et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990, 82:1636-1640.
20. Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013, 31:287-304.
21. Miyamoto H., Yang Z., Chen Y.T., Ishiguro H., Uemura H., Kubota Y., et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007, 99:558-568.
22. Johnson A.M., O'Connell M.J., Miyamoto H., Huang J., Yao J.L., Messing E.M., et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol 2008, 8:7.
23. Johnson A.M., O'Connell M.J., Messing E.M., Reeder J.E. Decreased bladder cancer growth in parous mice. Urology 2008, 72:470-473.